Innovative Medicine

Innovative Medicine

February 21, 2014

Janssen Initiates CREDENCE Study in Patients with Type 2 Diabetes and Diabetic Nephropathy

Trial Seeks to Examine the Effects of INVOKANA® on the Progression of Diabetic Nephropathy

Innovative Medicine

February 21, 2014

VOKANAMETTM (canagliflozin and metformin fixed dose combination) receives positive CHMP opinion recommending approval in the European Union for the treatment of adults with type 2 diabetes[1]

Innovative Medicine

February 14, 2014

FDA Issues Complete Response Letters for Use of XARELTO® (rivaroxaban) to Reduce the Risk of Secondary Cardiovascular Events and Stent Thrombosis in Patients with Acute Coronary Syndrome

Innovative Medicine

February 12, 2014

IMBRUVICA™ (ibrutinib) Now Approved in the U.S. for Patients with Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

Innovative Medicine

February 6, 2014

Johnson & Johnson Ranked as Pharma Industry’s Most Productive Innovator for the Second Consecutive Year

Innovative Medicine

January 9, 2014

Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and Announces Multiple, Diverse, Early-Stage Collaborations with Academia and Biotech

Innovative Medicine

January 8, 2014

Janssen Pharmaceutical Companies of Johnson & Johnson Submit Citizen Petition to the U.S. FDA Regarding Naming of Biosimilars

Ask Agency to require that biosimilars bear distinguishable names to enhance patient safety

Innovative Medicine

January 7, 2014

Independent Data Monitoring Committee Recommends Early Stopping of Phase 3 Study of Ibrutinib in Relapsed/Refractory CLL/SLL Patients Based on a Planned Interim Analysis

Innovative Medicine

December 12, 2013

FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes